Common use of Clinical Trial Register Clause in Contracts

Clinical Trial Register. Each of GSK and TELETHON-HSR shall have the right, to the extent permitted by and in compliance with all applicable laws and regulations, to publish summaries of results from any human Clinical Trials conducted by such Party under this Agreement on its Clinical Trials registry, without requiring the consent of the other Party, subject to the last sentence of this Section 9.6; provided, however, that GSK shall have no right, without the consent of TELETHON-HSR, to so publish data generated by TELETHON-HSR prior to GSK’s exercise of its Option with respect to the relevant Vectors under the relevant Collaboration Program, and, after the exercise of its Option to such Collaboration Program, GSK shall have the right to so publish any previously existing and/or any subsequently arising data that is or may be generated by either TELETHON-HSR or GSK or by their respective Affiliates or Sublicensees with respect to the relevant Vector(s) without obtaining the consent of TELETHON-HSR, except with respect to any Vectors which are being pursued under a TELETHON-HSR *** Confidential Treatment Requested *** Development Program after termination by GSK of such Vectors as GSK Development Vectors or after GSK declines to exercise its Option with respect to such Collaboration Program. In addition, after the exercise of its Option by GSK to a particular Collaboration Program, TELETHON-HSR shall not have the right to publish any of such data, without the prior consent of GSK, pertaining to the relevant Vectors or the Collaboration Program, except with respect to any Vectors which are being pursued under a TELETHON-HSR Development Program after termination by GSK of such Vectors as GSK Development Vectors. The Parties shall discuss and reasonably cooperate in order to facilitate the process to be employed in order to ensure the publication of any such summaries of human Clinical Trials data and results as required on the Clinical Trial registry of each respective Party, and shall provide the other Party via submission to the Joint Patent Subcommittee established under Section 3.2(g), at least [***] prior notice to review the Clinical Trials results to be published for the purposes of preparing any necessary Patent filings.

Clinical Trial Register. Each of GSK and TELETHON-HSR Dynavax shall have the right, to the extent permitted by and in compliance with all applicable laws and regulations, right to publish summaries of results from any human Clinical Trials clinical trials conducted by such Party under this Agreement on its Clinical Trials clinical trials registry, without requiring the consent of the other Party, subject to the last sentence of this Section 9.69.7; provided, however, that GSK shall have no right, without the consent of TELETHON-HSRDynavax, to so publish data generated by TELETHON-HSR Dynavax prior to GSK’s exercise of its Option with respect to the relevant Vectors Compounds under the relevant Collaboration Dynavax Program, and, after the exercise of its Option to such Collaboration Dynavax Program, GSK shall have the right to so publish any previously existing and/or any subsequently arising data that is or may be generated by either TELETHON-HSR Dynavax or GSK or by their respective Affiliates or Sublicensees with respect to the relevant Vector(sCompound(s) without obtaining the consent of TELETHON-HSRDynavax, except with respect to any Vectors Compounds which are being pursued under a TELETHON-HSR *** Confidential Treatment Requested *** Dynavax Development Program after termination by GSK of such Vectors Compounds as GSK Development Vectors Compounds or after GSK declines to exercise its Option with respect to such Collaboration Dynavax Program. In addition, after the exercise of its Option by GSK to a particular Collaboration Dynavax Program, TELETHON-HSR Dynavax shall not have the right to publish any of such data, without the prior consent of GSK, pertaining to the relevant Vectors Compounds or the Collaboration Dynavax Program, except with respect to any Vectors Compounds which are being pursued under a TELETHON-HSR Dynavax Development Program after termination by GSK of such Vectors Compounds as GSK Development VectorsCompounds. The Parties shall discuss and reasonably cooperate in order to facilitate the process to be employed in order to ensure the publication of any such summaries of human Clinical Trials clinical trials data and results as required on the Clinical Trial clinical trial registry of each respective Party, and shall provide the other Party via submission to the Joint Patent Subcommittee established under Section 3.2(g)3.1.8, at least [***[ * ] Calendar Days prior notice to review the Clinical Trials clinical trials results to be published for the purposes of preparing any necessary Patent filings.

Clinical Trial Register. Each of GSK and TELETHON-HSR PROSENSA shall have the right, to the extent permitted by and in compliance with all applicable laws and regulations, right to publish summaries of results from any human Clinical Trials conducted by such Party under this Agreement on its Clinical Trials registry, without requiring the consent of the other Party, subject to the last sentence of this Section 9.6; provided, however, that GSK shall have no right, without the consent of TELETHON-HSRPROSENSA, to so publish data generated by TELETHON-HSR PROSENSA prior to GSK’s exercise of its Option with respect to the relevant Vectors Compounds under the relevant PROSENSA Collaboration Program, and, after the exercise of its Option to such PROSENSA Collaboration Program, GSK shall have the right to so publish any previously existing and/or any subsequently arising data that is or may be generated by either TELETHON-HSR PROSENSA or GSK or by their respective Affiliates or Sublicensees with respect to the relevant Vector(sCompound(s) without obtaining the consent of TELETHON-HSRPROSENSA, except with respect to any Vectors Compounds which are being pursued under a TELETHON-HSR *** Confidential Treatment Requested *** PROSENSA Development Program after termination by GSK of such Vectors Compounds as GSK Development Vectors Compounds or after GSK declines to exercise its Option with respect to such PROSENSA Collaboration Program. In addition, after the exercise of its Option by GSK to a particular PROSENSA Collaboration Program, TELETHON-HSR PROSENSA shall not have the right to publish any of such data, without the prior consent of GSK, pertaining to the relevant Vectors Compounds or the PROSENSA Collaboration Program, except with respect to any Vectors Compounds which are being pursued under a TELETHON-HSR PROSENSA Development Program after termination by GSK of such Vectors Compounds as GSK Development VectorsCompounds. The Parties shall discuss and reasonably cooperate in order to facilitate the process to be employed in order to ensure the publication of any such summaries of human Clinical Trials data and results as required on the Clinical Trial registry of each respective Party, and shall provide the other Party via submission to the Joint Patent Subcommittee established under Section 3.2(g3.1(h), at least [***] * * * * * prior notice to review the Clinical Trials results to be published for the purposes of preparing any necessary Patent filings.